Company intelligence / Profile preview

EGEIRO Pharma

Gosselies, Wallonia, Belgiumegeiro.be ↗

Ownership: Private
Employees: ~14
Development stage: Preclinical

Overview

EGEIRO Pharma was formed from the renaming of TheraVet after integrating a clinical program from H4Orphan focused on idiopathic pulmonary fibrosis. The company aimed to develop targeted treatments for this severe lung disease. As of March 2025, the company declared bankruptcy and ceased operations.

Prior to its closure, it had also developed veterinary osteoarticular treatments under the TheraVet brand.

Financials showed negative EBITDA and net profit margins prior to bankruptcy.

No recent clinical trial results are available.

Therapeutic areas: Pulmonology
Modalities: Not explicitly stated; likely small molecules or biologics for idiopathic pulmonary fibrosis based on typical approaches in the field (inferred)
Industry: Biotech

Partnerships

Strategic agreement with H4Orphan leading to asset contribution and new direction focused on IPF.

Beyond the preview

Go deeper on EGEIRO Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EGEIRO Pharma.

Explore the full profile